Related Experiment Videos
[Platelet antiaggregants and coronary pathology]
Insights
Aspirin (acetylsalicylic acid) effectively reduces coronary thrombosis and myocardial infarction in high-risk patients. Its role in preventing heart attacks in healthy individuals requires further investigation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Atherosclerosis of coronary arteries poses significant risks for thrombosis and myocardial infarction.
- Platelet inhibitors are crucial in managing these cardiovascular events.
Purpose:
- To review the efficacy of aspirin (acetylsalicylic acid) in preventing coronary thrombosis and myocardial infarction across various clinical scenarios.
- To compare aspirin's effectiveness with other anticoagulants like heparin and anti-vitamin K agents.
Summary:
- Aspirin, in doses of 160-1500 mg daily, is proven effective in high-risk situations including post-myocardial infarction, acute myocardial infarction, unstable angina, post-aorto-coronary bypass, and post-coronary artery dilatation.
- Studies comparing aspirin to heparin and anti-vitamin K agents show no significant difference in effectiveness.
- The potential benefit of aspirin in preventing myocardial infarction in healthy individuals remains uncertain.
Impact:
- Aspirin is a cornerstone therapy for preventing thrombotic events in patients with established coronary artery disease.
- Understanding aspirin's mechanism, which involves interrupting the cascade from plaque rupture to thrombosis, is key to its therapeutic application.
- Further research is needed to clarify the role of aspirin in primary prevention of myocardial infarction.
Abstract:
Platelet inhibitors have widely been studied in various clinical situations resulting from atherosclerosis of the coronary arteries. At present, aspirin is virtually the only drug that has proved to be effective in all cases where the risk of coronary thrombosis was very high. Administered in daily doses of 160 to 1,500 mg, acetylsalicylic acid reduces the frequency of coronary thrombosis and its consequence, myocardial infarction, in the following clinical situations: year following myocardial infarction, acute phase of myocardial infarction, unstable angina, year following aorto-coronary bypass, days following dilatation of the coronary arteries. Acetylsalicylic acid has been compared with heparin and anti-vitamin K agents in four trial: whatever the model studied, no difference was found in the effectiveness of the two treatments tested. Aspirin ha recently been reported as preventing myocardial infarction in healthy subjects. The practical value of this finding is questionable. The various effects of aspirin have been ascribed to the fact that it interrupts a cascade of events ranging from rupture of atherosclerosis plaques to arterial thrombosis.